Patents by Inventor Charles RUDIN

Charles RUDIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SENECA VALLEY VIRUS (SVV) CELLULAR RECEPTOR TARGETED ONCOTHERAPY
    Publication number: 20240139267
    Abstract: A method for selecting cancer patient for treatment with Seneca Valley Virus (SVV) by determining expression of ANTXR1 in a cancerous tissue in a cancer patient; and designating the cancer patient as a candidate for treatment with SVV if normal levels or elevated levels of ANTXR1 expression is detected in the cancerous tissue. Also a method for treating a cancer patient with SVV is disclosed.
    Type: Application
    Filed: August 28, 2023
    Publication date: May 2, 2024
    Inventors: Linde MILES, John POIRIER, Charles RUDIN
  • ANTI-DLL3 ANTIBODY-DRUG CONJUGATE
    Publication number: 20240115721
    Abstract: It is an object of the present invention to provide an antibody-drug conjugate of an antibody binding to DLL3 and a drug having antitumor activity, a pharmaceutical composition comprising the antibody-drug conjugate and having therapeutic effects on a tumor, a method for treating a tumor using the antibody-drug conjugate or the pharmaceutical composition, and the like. The present invention provides an antibody-drug conjugate of an antibody binding to DLL3 and a drug having antitumor activity, a pharmaceutical composition comprising the antibody or the antibody-drug conjugate, and a method for treating a tumor.
    Type: Application
    Filed: January 13, 2022
    Publication date: April 11, 2024
    Applicants: MEMORIAL SLOAN KETTERING CANCER CENTER, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: John T. POIRIER, Charles RUDIN, Jason LEWIS, Abdul KHAN, David ANDREW, Xinlei CHEN, Ivo LORENZ, Hironori MATSUNAGA
  • ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
    Publication number: 20240115720
    Abstract: The present invention provides a novel anti-DLL3 antibody-pyrrolodiazepine derivative and a novel anti-DLL3 anti-body-pyrrolodiazepine derivative conjugate using the same.
    Type: Application
    Filed: January 13, 2022
    Publication date: April 11, 2024
    Applicants: MEMORIAL SLOAN KETTERING CANCER CENTER, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: John T. POIRIER, Charles RUDIN, Jason LEWIS, Abdul KHAN, David ANDREW, Xinlei CHEN, Ivo LORENZ, Hironori MATSUNAGA
  • Seneca valley virus (SVV) cellular receptor targeted oncotherapy
    Patent number: 11738058
    Abstract: A method for selecting cancer patient for treatment with Seneca Valley Virus (SVV) by determining expression of ANTXR1 in a cancerous tissue in a cancer patient; and designating the cancer patient as a candidate for treatment with SVV if normal levels or elevated levels of ANTXR1 expression is detected in the cancerous tissue. Also a method for treating a cancer patient with SVV is disclosed.
    Type: Grant
    Filed: August 19, 2021
    Date of Patent: August 29, 2023
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Linde Miles, John Poirier, Charles Rudin
  • DLL3-TARGETING ANTIBODIES AND USES THEREOF
    Publication number: 20220348648
    Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to delta-like protein 3 (DLL3). The antibodies of the present technology are useful in methods for detecting and treating a DLL3-associated cancer in a subject in need thereof.
    Type: Application
    Filed: July 8, 2020
    Publication date: November 3, 2022
    Inventors: John T. POIRIER, Charles RUDIN, Jason LEWIS, Abdul KHAN, David ANDREW, Xinlei CHEN, Ivo LORENZ
  • SENECA VALLEY VIRUS (SVV) CELLULAR RECEPTOR TARGETED ONCOTHERAPY
    Publication number: 20220054564
    Abstract: A method for selecting cancer patient for treatment with Seneca Valley Virus (SVV) by determining expression of ANTXR1 in a cancerous tissue in a cancer patient; and designating the cancer patient as a candidate for treatment with SVV if normal levels or elevated levels of ANTXR1 expression is detected in the cancerous tissue. Also a method for treating a cancer patient with SVV is disclosed.
    Type: Application
    Filed: August 19, 2021
    Publication date: February 24, 2022
    Inventors: Linde MILES, John POIRIER, Charles RUDIN
  • Seneca Valley Virus (SVV) cellular receptor targeted oncotherapy
    Patent number: 11096972
    Abstract: A method for selecting cancer patient for treatment with Seneca Valley Virus (SVV) by determining expression of ANTXR1 in a cancerous tissue in a cancer patient; and designating the cancer patient as a candidate for treatment with SVV if normal levels or elevated levels of ANTXR1 expression is detected in the cancerous tissue. Also a method for treating a cancer patient with SVV is disclosed.
    Type: Grant
    Filed: January 20, 2020
    Date of Patent: August 24, 2021
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Linde Miles, John Poirier, Charles Rudin
  • SENECA VALLEY VIRUS (SVV) CELLULAR RECEPTOR TARGETED ONCOTHERAPY
    Publication number: 20200222480
    Abstract: A method for selecting cancer patient for treatment with Seneca Valley Virus (SVV) by determining expression of ANTXR1 in a cancerous tissue in a cancer patient; and designating the cancer patient as a candidate for treatment with SVV if normal levels or elevated levels of ANTXR1 expression is detected in the cancerous tissue. Also a method for treating a cancer patient with SVV is disclosed.
    Type: Application
    Filed: January 20, 2020
    Publication date: July 16, 2020
    Inventors: Linde Miles, John Poirier, Charles Rudin
  • Seneca valley virus (SVV) cellular receptor targeted oncotherapy
    Patent number: 10537599
    Abstract: A method for selecting cancer patient for treatment with Seneca Valley Virus (SVV) by determining expression of ANTXR1 in a cancerous tissue in a cancer patient; and designating the cancer patient as a candidate for treatment with SVV if normal levels or elevated levels of ANTXR1 expression is detected in the cancerous tissue. Also a method for treating a cancer patient with SVV is disclosed.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: January 21, 2020
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Linde Miles, John Poirier, Charles Rudin
  • SENECA VALLEY VIRUS (SVV) CELLULAR RECEPTOR TARGETED ONCOTHERAPY
    Publication number: 20190030099
    Abstract: A method for selecting cancer patient for treatment with Seneca Valley Virus (SVV) by determining expression of ANTXR1 in a cancerous tissue in a cancer patient; and designating the cancer patient as a candidate for treatment with SVV if normal levels or elevated levels of ANTXR1 expression is detected in the cancerous tissue. Also a method for treating a cancer patient with SVV is disclosed.
    Type: Application
    Filed: December 2, 2016
    Publication date: January 31, 2019
    Inventors: Linde MILES, John POIRIER, Charles RUDIN